Mukherjee A, Biswas S, Roy I
Acta Pharmacol Sin. 2025; .
PMID: 39890942
DOI: 10.1038/s41401-024-01455-w.
Kim S, Lim W
Cogn Neurodyn. 2024; 18(5):2909-2924.
PMID: 39555304
PMC: 11564723.
DOI: 10.1007/s11571-024-10125-w.
Basavarajappa B, Subbanna S
Biomolecules. 2024; 14(10).
PMID: 39456229
PMC: 11506053.
DOI: 10.3390/biom14101296.
Shafie A, Ashour A, Anwar S, Anjum F, Hassan M
Arch Pharm Res. 2024; 47(6):571-595.
PMID: 38764004
DOI: 10.1007/s12272-024-01499-w.
Placido E, Gomes Welter P, Wink A, Karasiak G, Outeiro T, Dafre A
Int J Mol Sci. 2023; 24(16).
PMID: 37628801
PMC: 10454852.
DOI: 10.3390/ijms241612607.
Deuterium in drug discovery: progress, opportunities and challenges.
Di Martino R, Maxwell B, Pirali T
Nat Rev Drug Discov. 2023; 22(7):562-584.
PMID: 37277503
PMC: 10241557.
DOI: 10.1038/s41573-023-00703-8.
Preliminary In Vitro and In Vivo Insights of In Silico Candidate Repurposed Drugs for Alzheimer's Disease.
Savva K, Zachariou M, Kynigopoulos D, Fella E, Vitali M, Kosofidou X
Life (Basel). 2023; 13(5).
PMID: 37240740
PMC: 10221567.
DOI: 10.3390/life13051095.
NHC-Ni catalyzed 1,3- and 1,4-diastereodivergent heterocycle synthesis from hetero-substituted enyne.
Yong X, Gao W, Lin X, Ho C
Commun Chem. 2023; 3(1):50.
PMID: 36703443
PMC: 9814851.
DOI: 10.1038/s42004-020-0299-9.
Current and Possible Future Therapeutic Options for Huntington's Disease.
Ferguson M, Kennedy C, Palpagama T, Waldvogel H, Faull R, Kwakowsky A
J Cent Nerv Syst Dis. 2022; 14:11795735221092517.
PMID: 35615642
PMC: 9125092.
DOI: 10.1177/11795735221092517.
A systematic review of minor phytocannabinoids with promising neuroprotective potential.
Stone N, Murphy A, England T, OSullivan S
Br J Pharmacol. 2020; 177(19):4330-4352.
PMID: 32608035
PMC: 7484504.
DOI: 10.1111/bph.15185.
Cause or compensation?-Altered neuronal Ca handling in Huntington's disease.
Mackay J, Nassrallah W, Raymond L
CNS Neurosci Ther. 2018; 24(4):301-310.
PMID: 29427371
PMC: 6489756.
DOI: 10.1111/cns.12817.
Huntington's Disease-Update on Treatments.
Wyant K, Ridder A, Dayalu P
Curr Neurol Neurosci Rep. 2017; 17(4):33.
PMID: 28324302
DOI: 10.1007/s11910-017-0739-9.
Synthesis of (±)-Tetrabenazine by Visible Light Photoredox Catalysis.
Orgren L, Maverick E, Marvin C
J Org Chem. 2015; 80(24):12635-40.
PMID: 26544155
PMC: 4684717.
DOI: 10.1021/acs.joc.5b02199.
A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
Chen S, Zhang X, Xie W, Qiu H, Liu H, Le W
CNS Neurosci Ther. 2015; 21(8):662-71.
PMID: 26122704
PMC: 6495663.
DOI: 10.1111/cns.12425.
Neural stem cells could serve as a therapeutic material for age-related neurodegenerative diseases.
Suksuphew S, Noisa P
World J Stem Cells. 2015; 7(2):502-11.
PMID: 25815135
PMC: 4369507.
DOI: 10.4252/wjsc.v7.i2.502.
An automated and quantitative method to evaluate progression of striatal pathology in Huntington's disease transgenic mice.
Liang X, Wu J, Egorova P, Bezprozvanny I
J Huntingtons Dis. 2015; 3(4):343-350.
PMID: 25575955
PMC: 4317287.
DOI: 10.3233/JHD-140128.
Neurotrophic natural products: chemistry and biology.
Xu J, Lacoske M, Theodorakis E
Angew Chem Int Ed Engl. 2013; 53(4):956-87.
PMID: 24353244
PMC: 3945720.
DOI: 10.1002/anie.201302268.
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease.
Brusa L, Orlacchio A, Stefani A, Galati S, Pierantozzi M, Iani C
Funct Neurol. 2013; 28(2):101-5.
PMID: 24125559
PMC: 3812731.
DOI: 10.11138/FNeur/2013.28.2.101.
Biological sources of inflexibility in brain and behavior with aging and neurodegenerative diseases.
Hong S, Rebec G
Front Syst Neurosci. 2012; 6:77.
PMID: 23226117
PMC: 3510451.
DOI: 10.3389/fnsys.2012.00077.
Therapeutic approaches to preventing cell death in Huntington disease.
Kaplan A, Stockwell B
Prog Neurobiol. 2012; 99(3):262-80.
PMID: 22967354
PMC: 3505265.
DOI: 10.1016/j.pneurobio.2012.08.004.
